OvaScience, Inc. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of Class Action Against OvaScience, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of November 15, 2013
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased OvaScience, Inc. (“OvaScience” or the “Company”) (NasdaqGM:OVAS) common stock between February 25, 2013 and September 10, 2013.
For more information, click here: http://zlk.9nl.com/ovascience-ovas/.
The complaint alleges that Defendants made false and/or misleading statements regarding the Company's business and operations. In particular, it is alleged that the Company falsely represented to investors and the Food and Drug Administration (“FDA”) that it believed its AUGMENT drug would qualify for designation as a 361 HCT/P, which allows human cellular- and tissue- based products to be tested and marketed without FDA licensure.
On September 11, 2013, the Company announced the receipt of a letter from the FDA in which the status of AUGMENT as a 361 HCT/P was questioned. The FDA also requested that OvaScience file an Investigational New Drug (IND) application, thus ensuring that the drug face mandatory clinical testing. The Company has suspended enrollment in AUGMENT in the U.S. and now plans to initiate sites for a study outside of the U.S. in 2014. Shares of OvaScience stock have fallen from a close of $14.28 per share on September 10, 2013 to a close of $9.83 on September 16, 2013.If you suffered a loss in OvaScience you have until November 15, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ovascience-ovas. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV